

Cover Figure

Electron microscopy image of microvesicles from the cell-free fraction of a G-CSF mobilized bone marrow. Taken from the article by Salvucci and colleagues, pages 818-826.

Hematology News

795 Novel insights on TLX1 function in T-ALL pave the way towards differentiation therapy
Kim De Keersmaecker

796 New opportunities and new problems for acute myeloid leukemia treatment
Idoya Lahortiga and Jan Cools

Editorials and Perspectives

797 Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?
Andrea Gallamini and Lale Kostakoglu

800 Optimizing investigator-led oncology research in Europe
Tiziano Barbui, Magnus Björkholm, Alois Gratwohl

Review Articles

805 Acute myeloid leukemia developing in patients with autoimmune diseases
Safaa M. Ramadan, Tamer M Fouad, Valentina Summa, Syed KH Hasan, and Francesco Lo-Coco

Original Articles and Brief Reports

Hematopoiesis & Hematopoietic Stem Cells

818 MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1
Ombretta Salvucci, Kan Jiang, Paola Gasperini, Dragan Maric, Jinfang Zhu, Shuhei Sakakibara, Georgina Espigol-Frigole, Shushang Wang, and Giovanna Tosato

Iron Metabolism & Its Disorders

827 Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis
Maria Mastrogiannaki, Pavle Matak, Jacques R.R. Mathieu, Stéphanie Delga, Patrick Mayeux, Sophie Vaulont, and Carole Peyssonnaud

Thalassemia Syndromes

835 Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response
Yesim Aydinok, Patricia Evans, Chantal Y. Manz, and John B. Porter

842 Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β -thalassemia major
Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, and Ali Taher

Molecular & Cellular Basis of Plasma Cell Disorders

849 Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
Simone Ferrero, Daniela Capello, Mirija Svaldi, Michela Boi, Daniela Gatti, Daniela Drandi, Davide Rossi, Sara Barbiero, Barbara Mantoan, Elisabetta Mantella, Manuela Zanni, Paola Ghione, Alessandra Larocca, Roberto Passera, Francesco Bertoni, Valter Gattei, Francesco Forconi, Luca Laurenti, Giovanni Del Poeta, Roberto Marasca, Sergio Cortelazzo, Gianluca Gaidano, Antonio Palumbo, Mario Boccadoro, and Marco Ladetto

Monoclonal Gammopathy of Undetermined Significance

854 Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study
Sigurdur Y. Kristinsson, Min Tang, Ruth M Pfeiffer, Magnus Björkholm, Lynn R. Goldin, Cecilie Blimark, Ulf-Henrik Mellqvist, Anders Wahlin, Ingemar Turesson, and Ola Landgren



Official Organ of the
European Hematology Association

Hemostasis

- 859** **Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation**
Jiong-Wei Wang, Dafna J. Groeneveld, Guy Cossemans, Richard J. Dirven, Karine M. Valentijn, Jan Voorberg, Pieter H. Reitsma, and Jeroen Eikenboom

Stem Cell Transplantation

- 867** **Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation**
Jan Joseph Melenhorst, Xin Tian, Dihua Xu, Netanya G. Sandler, Philip Scheinberg, Angelique Biancotto, Priscila Scheinberg, John Phil McCoy Jr, Nancy F. Hensel, Zach McIver, Daniel C Douek, and Austin John Barrett

Cell Therapy and Immunotherapy

- 874** **Varicella-zoster virus glycoproteins B and E are major targets of CD4⁺ and CD8⁺ T cells reconstituting during zoster after allogeneic transplantation**
Patrick Kleemann, Eva Distler, Eva M. Wagner, Simone Thomas, Sebastian Klobuch, Steffi Aue, Elke Schmäurer, Hansjörg Schild, Matthias Theobald, Bodo Plachter, Stefan Tenzer, Ralf G. Meyer, and Wolfgang Herr

Chemotherapy Toxicities and Complications

- 883** **Clinical cardiac safety profile of nilotinib**
Theo D. Kim, Philipp le Coutre, Michaela Schwarz, Peggy Grille, Michal Levitin, Suzanne Fateh-Moghadam, Francis J. Giles, Bernd Dörken, Wilhelm Haverkamp, and Clemens Köhncke

Myelodysplastic Syndromes

- 890** **Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival**
Csaba Bődör, Aline Renneville, Matthew Smith, Aurélie Charazac, Sameena Iqbal, Pascaline Étancelin, Jamie Cavenagh, Michael J Barnett, Karolína Kramarzová, Biju Krishnan, András Matolcsy, Claude Preudhomme, Jude Fitzgibbon, and Carolyn Owen

- 895** **Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes**
Alex F. Sandes, Mihoko Yamamoto, Sergio Matarraz, Maria de Lourdes L.F. Chauffaille, Sandra Quijano, Antonio López, Tsutomu Oguro, Eliza Y. S. Kimura, and Alberto Orfao

Chronic Myeloid Leukemia

- 903** **Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia**
Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, and Kazuma Ohyashiki

- 907** **Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib**
Deborah L. White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K. Frede, Phuong Dang, Daniela Cilloni, Peter Lin, Lidia Mongay, Richard Woodman, Paul Manley, Cassandra Slader, Dong Wook Kim, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, and Timothy P. Hughes

Acute Myeloid Leukemia

- 915** **Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission**
Masamitsu Yanada, Saiko Kurosawa, Takuhiro Yamaguchi, Takuya Yamashita, Yukiyooshi Moriuchi, Hiroatsu Ago, Jin Takeuchi, Hirohisa Nakamae, Jun Taguchi, Toru Sakura, Yasushi Takamatsu, Fusako Waki, Hiroki Yokoyama, Masato Watanabe, Nobuhiko Emi, and Takahiro Fukuda

Adult Acute Lymphoblastic Leukemia

- 919** **Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?**
Guilin Tang, Zhuang Zuo, Deborah A. Thomas, Pei Lin, Dingsheng Liu, Ying Hu, Hagop M. Kantarjian, Carlos Bueso-Ramos, L. Jeffrey Medeiros, and Sa A. Wang



Official Organ of the
European Hematology Association

Molecular & Cellular Basis of Lymphoid Malignancy

- 926** **A20 inactivation in ocular adnexal MALT lymphoma**
Yingwen Bi, Naiyan Zeng, Estelle Chanudet, Yuanxue Huang, Rifat A. Hamoudi, Hongxiang Liu, Gehong Dong, A James Watkins, Steven C. Ley, Lifan Zou, Rongjia Chen, Xiongze Zhu, and Ming-Qing Du

Hodgkin's Lymphoma

- 931** **Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs**
Tarec Christoffer El-Galaly, Karen Juul Mylam, Peter Brown, Lena Specht, Ilse Christiansen, Lars Munksgaard, Hans Erik Johnsen, Annika Loft, Anne Bukh, Victor Iyer, Anne Lerberg Nielsen, and Martin Hutchings

Non-Hodgkin's Lymphomas

- 937** **Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone**
Daniel O. Persky, David Dornan, Bryan H. Goldman, Rita M. Brazier, Richard I. Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, Thomas P. Miller, and Lisa M. Rimsza

Chronic Lymphocytic Leukemia

- 943** **Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells**
Paula X. Fernández-Calotti, Mónica Lopez-Guerra, Dolores Colomer, and Marçal Pastor-Anglada
- 952** **Physical contact with endothelial cells through β_1 - and β_2 - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells**
Rossana Maffei, Stefania Fiorcari, Jenny Bulgarelli, Silvia Martinelli, Ilaria Castelli, Silvia Deaglio, Giulia Debbia, Marcella Fontana, Valeria Coluccio, Goretta Bonacorsi, Patrizia Zucchini, Franco Narni, Giuseppe Torelli, Mario Luppi, and Roberto Marasca

Online-Only Articles

- e18** **Characterization of potential CD138 negative myeloma "stem cells"**
Jacob H. Christensen, Pia V. Jensen, Ida B. Kristensen, Niels Abildgaard, Marianne Lodahl, and Thomas Rasmussen
- e21** **Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma**
Alessandra Romano, Calogero Vetro, Daniela Donnarumma, Stefano Forte, Massimo Ippolito, and Francesco Di Raimondo
- e24** **Reply to "Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma"** *Haematologica* 2012;97(6):e21-3
Luis F. Porrata and Svetomir N. Markovic

Continuing Medical Education

Enhancement of fludarabine sensitivity by all-trans retinoic acid in chronic lymphocytic leukemia cells

Immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes

Long-term iron chelation with in patients with beta-thalassemia major

Therapy-related precursor B-acute lymphoblastic leukemia